NCT05930808View on ClinicalTrials.gov

Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong)

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

June 18, 2023

Study Completion Date

June 18, 2023

Conditions
Healthy
Interventions
DRUG

First Test Concor (Fasted)

Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.

DRUG

First Reference Concor (Fasted)

Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition

DRUG

First Test Concor (Fed)

Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.

DRUG

First Reference Concor (Fed)

Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.

Trial Locations (1)

Unknown

Beijing Friendship Hospital, Capital Medical University-Drug Clinical Trial Organization Office, Beijing

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY